Mohamed Kohla
Overview
Explore the profile of Mohamed Kohla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
55
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shousha H, Barakat E, Rewisha E, El-Kassas M, Moustafa E, Said M, et al.
Arab J Gastroenterol
. 2025 Jan;
26(1):94-103.
PMID: 39794187
Background And Study Aims: Few studies have considered patients treated with trans-arterial chemoembolization (TACE) for non-viral-induced hepatocellular carcinoma (HCC), with some reporting that those patients may have larger tumors, emphasizing...
2.
El-Kassas M, Barakat E, Shousha H, Kohla M, Said M, Moustafa E, et al.
Eur J Gastroenterol Hepatol
. 2024 Dec;
37(1):83-93.
PMID: 39621880
Background: Viral hepatitis B and C are the leading causes of hepatocellular carcinoma (HCC). With obesity, metabolic-related disorders are increasingly associated with a higher incidence of nonviral HCC. This study...
3.
Abdel-Samiee M, Ibrahim E, Kohla M, Abdelsameea E, Salama M
World J Gastrointest Pharmacol Ther
. 2024 Nov;
15(6):97381.
PMID: 39534523
The global incidence of nonalcoholic fatty liver disease (NAFLD) is escalating considerably. NAFLD covers a range of liver conditions from simple steatosis to the more severe form known as nonalcoholic...
4.
Kohla M, Ashour R, Taha H, El-Abd O, Osman M, Abozeid M, et al.
BMC Gastroenterol
. 2024 Sep;
24(1):318.
PMID: 39294585
Background: Accurate staging is necessary for predicting hepatocellular carcinoma (HCC) prognosis and guiding patient management. The Barcelona Clinic Liver Cancer (BCLC) staging system has limitations due to heterogeneity observed among...
5.
Alhaddad O, Gomaa A, Shamandy M, Kohla M, Edrees A, Ashour R
Rom J Intern Med
. 2024 Sep;
62(4):430-439.
PMID: 39217454
Background: Hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE) have a diverse range of outcomes due to their high degree of heterogeneity. Therefore, different predictive scoring systems have been created...
6.
Mosbeh A, Abdelmaguid W, Ezzat S, Kohla M, Sultan M, Abdel-Rahman M
Asian Pac J Cancer Prev
. 2023 Sep;
24(9):3165-3168.
PMID: 37774068
Objective: Study the frequency of codon 7 (c.747 G>T, p. R249S) mutation associated with Aflatoxin B1 (AFB1) exposure in Egyptian patients with hepatocellular carcinoma (HCC). Methods: We utilized restriction fragment...
7.
Bonacini M, Kassamali F, Kari S, Lopez Barrera N, Kohla M
World J Hepatol
. 2021 Aug;
13(7):763-773.
PMID: 34367497
The aim of this review is to assess the evidence regarding racial differences in the prevalence and severity of nonalcoholic fatty liver disease (NAFLD). We reviewed the published literature that...
8.
Sapena V, Enea M, Torres F, Celsa C, Rios J, Rizzo G, et al.
Gut
. 2021 Mar;
71(3):593-604.
PMID: 33741640
Objective: The benefit of direct-acting antivirals (DAAs) against HCV following successful treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of individual patient data assessed HCC recurrence risk following DAA...
9.
Kohla M, Iwata S, Ea R, Keyhan S, Taylor R, Yu M, et al.
Dig Dis Sci
. 2011 Sep;
57(3):771-6.
PMID: 21948357
Unlabelled: Liver fibrosis progression in hepatitis C virus (HCV) infection has been in part associated with race/ethnicity. Little is known of the frequency of clinical cirrhosis in Asian patients in...